| abstract |
The present invention provides N6-disubstituted purine derivatives of the general formula: <IMAGE> (I) wherein R1 and R4 are the same or different and each represents a hydrogen or halogen atom or an -NR6R7 group, R2 and R3 are the same or different and each represents a C1-C6 alkyl radical, a C2-C6 alkenyl radical, a C3-C7 cycloalkyl radical, a phenalkyl radical containing up to 4 carbon atoms in the alkyl moiety, which can be straight-chained or branched, the phenyl moiety of which can be substituted one or more times by halogen, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio or trifluoromethyl; a furylmethyl or furylethyl radical, a thiophenemethyl or thiopheneethyl radical, a pyridylmethyl or pyridylethyl radical optionally substituted by a C1-C4 alkyl radical, an indanyl radical or a tetrahydronaphthyl radical, R5 is a hydrogen atom, a tetrahydrofuranyl or tetrahydropyranyl radical or a C1-C10 radical which is optionally substituted one or more times by hydroxyl, C1-C6 alkanoyloxy, C1-C6 alkoxycarbonyl, C2-C6 carboxyalkanoyloxy, C2-C6 hydroxyalkoxy, C3-c6 dihydroxyalkoxy, carboxyl, cyano or 1H-tetrazol-5-yl radical, R6 and R7 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl radical or together represent a C2-C5 alkylene radical optionally interrupted by oxygen, sulphur or an NR8 group and R8 is a hydrogen atom or a C1-C6 alkyl radical; as well as the pharmacologically acceptable salts thereof. |